Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis. Issue 13 (July 2020)

• Record Type: Journal Article
• Authors: Estrada, Esteban; Décima, Jose L; Rodríguez, Marcelo; Di Tomaso, Marianela; Roberti, Javier
• Is Part Of: Clinical medicine insights. Arthritis and musculoskeletal disorders. Issue 13(2020)
• Publication Date: 2020-07
• Subjects: Platelet-rich plasma -- bone marrow aspirate concentrate -- adipose-derived mesenchymal stem cell -- osteoarthritis -- knee; Arthritis -- Periodicals; Musculoskeletal system -- Abnormalities -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; 616.7005
• DOI: 10.1177/1179544120931086
• Languages: English
• ISSNs: 1179-5441

Abstract

Objective: The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores. Methods: A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups. Results: Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type. Conclusions: Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.